onc brain

Studies · 71

• 🧠 CNS · 2026-06-09
  FIRESTORM
  5-yr PFS 65.8% vs 38.8%, HR 0.40 favoring dose-escalated RT in high-risk meningioma; retrospective IPD meta-analysis.
• 🧠 CNS · 2026-06-09
  NRG Oncology RTOG 0539
  10-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk meningioma with risk-adapted observation or RT (median f/u ~12yr).
• 🎀 Breast · 2026-06-09
  RAPCHEM (BOOG 2010-03)
  10-yr locoregional recurrence 2.9% overall with risk-stratified RT de-escalation after NAC + surgery in cN1 breast cancer.
• 🌰 Prostate · 2026-06-04
  PrTK03 (aglatimagene besadenovec + EBRT)
  DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer.
• 👄 Head & Neck · 2026-06-04
  AREST
  3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS.
• 🌀 GI Lower · 2026-06-02
  mRCAT-III
  pCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC.
• 🎀 Breast · 2026-06-02
  Breast RT + Systemic Therapy Concurrency Review (Speers)
  T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.
• 🫁 Thoracic / Lung · 2026-06-02
  ES-SCLC Concurrent TRT + Chemoimmunotherapy (LBA8005)
  mOS 10.0 vs 11.8mo, HR 1.14, p=0.40: concurrent TRT adds no OS benefit to chemoIO in ES-SCLC.
• 🌀 GI Lower · 2026-06-01
  ctDNA surveillance in non-operative rectal cancer management
  ctDNA sensitivity only 41% for local regrowth vs 74% for distant mets in 110 NOM rectal pts; risk stratifies but cannot replace imaging.
• 🫁 Thoracic / Lung · 2026-06-01
  DeLLphi-304 (tarlatamab CNS outcomes)
  CNS PFS HR 0.54 (ITT), HR 0.40 in brain mets; CNS CR 14.9% vs 5.4% with tarlatamab vs chemo 2L SCLC.
• 🌰 Prostate · 2026-05-31
  PROTEUS
  53.0% (APA) and 60.7% (ADT) of MFS events PSMA PET-detected; APA+ADT vs ADT benefit in BCR prostate hotly contested.
• 🌰 Prostate · 2026-05-31
  COMPPARE
  No sig difference (bowel urgency 5.7% vs 6%, p=0.28; 3-yr BCF 98.0% vs 97.9%) between proton and IMRT in de novo localized prostate.
• 🌰 Prostate · 2026-05-31
  CAN-2409
  DFS HR 0.70 vs placebo (p=0.0155), driven by 2yr biopsy pCR 80.4% vs 63.6%; OS/PCSM immature at 50.3mo.
• 🌰 Prostate · 2026-05-31
  ENZARAD
  MFS HR 0.88 (p=0.34), OS HR 0.87 (p=0.40); enzalutamide added to RT+2y ADT did not improve outcomes in high-risk localized PCa.
• 🌀 GI Lower · 2026-05-31
  MIRACLE-2
  68% ORR, median OS 23.2mo, 18% NED in MSS unresectable metastatic rectal ca (N=50).
• 🟡 Hepatobiliary · 2026-05-31
  RASolute 302
  Daraxonrasib vs IC chemo in 2L RAS G12 mPDAC: mOS 13.2 vs 6.6 mo, HR 0.40 (0.30-0.54), p<0.001.
• 💧 Bladder · 2026-05-30
  RAD-IO
  12-month DFS 80% (40/50; 95% CI 0.67-0.89) with durvalumab + chemoRT in MIBC, clearing GO threshold ≥75%; single-arm.
• 💧 Bladder · 2026-05-30
  MIBC Management Post-pCR / Bladder-Sparing Session
  Durvalumab + CRT (55 Gy/20 fr) feasible in 54 MIBC (87% full RT); pCR after NAC carries 85% 5-yr OS per SWOG 8710.
• 🌰 Prostate · 2026-05-30
  NRG Clinico-Transcriptomic Risk Stratification (Abstract 5000)
  22-gene GC independently predicts MFS, DM, and OS; combined NRG score reclassifies ~25% discordant NCCN high-risk pts for AAP intensification.
• 🌰 Prostate · 2026-05-30
  A-DREAM (ALLIANCE mAPMS)
  ADT+ARPI interruption in mHSPC: 41% treatment-free with eugonadal T at 18mo (1° EP); 38.5% still off-tx at 26.9mo FU.
• 🌰 Prostate · 2026-05-30
  ENZAMET + Decipher Biomarker Analysis
  Decipher >0.85 identifies mHSPC pts with OS benefit from docetaxel intensification; IPTW interaction p=0.04, HR 0.75 (0.43-1.33).
• 🌰 Prostate · 2026-05-30
  ARACOG (AFT-47)
  MCCD median -36.1 (ENZ) vs -15.8 (DAR) at 24wk, p=0.009; enzalutamide caused significantly greater cognitive decline.
• 🌰 Prostate · 2026-05-30
  TALAPRO-3
  3yr rPFS 77% vs 56% (HR 0.48, p<0.001) favoring talazoparib+enza+ADT in HRR-deficient mHSPC.
• 🫁 Thoracic / Lung · 2026-05-30
  CHRYSALIS-2 (1L Ami+Laz, Atypical EGFR+)
  Median OS 41.0 mo (95% CI 27.7-NE) with ami+laz in 1L atypical EGFR+ advanced NSCLC; single-arm, n=49.
• 🫁 Thoracic / Lung · 2026-05-30
  ESAONA
  Intracranial ORR 95.5% vs 79.6% (p=0.0004), iPFS HR 0.46 favoring asandeutertinib over osimertinib in 1L EGFR+ NSCLC with brain mets.
• 🫁 Thoracic / Lung · 2026-05-30
  OptiTROP-Lung05
  mPFS NR vs 5.7mo, HR 0.35 (0.26-0.47), p<0.0001 favoring sac-TMT + pembro in 1L PD-L1+ NSCLC.
• 🎀 Breast · 2026-05-30
  PREPEC
  BREAST-Q chest score 79.2 vs 74.3 (diff 4.8, p=0.01) favoring pre-pectoral IBBR; implant loss 21% vs 15%.
• 🍽️ GI Upper · 2026-05-30
  Neo-CRAG
  Adding neoadj CRT to peri-op XELOX: mDFS 52.7 vs 24.4 mo, mOS 67.5 vs 37.6 mo in high-risk LAGC.
• 🧠 CNS · 2026-05-30
  ROADS
  Surg bed recurrence 1% (GT) vs 12% (SRS); 2yr OS 62% vs 36% favoring GammaTile in resected brain mets >2cm.
• 🤝 Supportive / QoL · 2026-05-30
  SPIN Score (Celiac Plexus SRS)
  89% pain response in SPIN-2 pts (baseline pain >6 + no prior neurotoxic chemo) vs 32% SPIN-0 after celiac SRS.
• 🫁 Thoracic / Lung · 2026-05-29
  Wait or Treat — NCT05236946 (Upfront vs Delayed Brain RT in Oncogene-mutated NSCLC)
  Upfront brain RT halves icPD (HR 0.35, p<0.001) but OS numerically favors delayed (HR 1.45, 2yr 60% vs 48%) in EGFR/ALK+ mNSCLC.
• 🎀 Breast · 2026-05-27
  SENOMAC
  5yr RFS 89.7% vs 88.7%, HR 0.89: SNB alone noninferior to ALND in cN0 breast cancer with 1-2 SN macrometastases.
• 🫁 Thoracic / Lung · 2026-05-26
  SWOG/NRG S1914
  No OS benefit from adding atezolizumab to SBRT (HR 1.15, p=0.63); closed for futility; G≥3 AEs 12% vs 2%.
• 🌐 Lymphoma · 2026-05-22
  EORTC Cutaneous Lymphoma RT Recommendations
  EORTC expert consensus formalizes low-dose RT recommendations across all primary cutaneous lymphoma entities; no RCT dose-comparison data exist.
• 🌰 Prostate · 2026-05-22
  PEACE V–STORM
  4-yr MFS 76% (ENRT) vs 63% (MDT), HR 0.62 favoring elective nodal RT for PET+ pelvic nodal prostate oligorecurrence.
• 🎀 Breast · 2026-05-22
  DBCG IMN2
  15-yr OS 65.0% vs 60.8%, HR 0.85 (0.76-0.94), p=0.0016 favoring IMNI in node-positive breast cancer with modern systemic therapy, N=4541.
• 💧 Bladder · 2026-05-21
  Bladder Adjuvant Radiotherapy
  2-yr LRFS 87.1% vs 76.0% (HR 0.43, p=0.04) favoring adj pelvic IMRT post-cystectomy in high-risk MIBC; DFS/OS NS.
• 🎀 Breast · 2026-05-21
  EORTC 22922/10925
  20yr OS HR 1.00 (null): BC mortality reduced HR 0.82 but non-BC deaths increased HR 1.26, offsetting benefit.
• 🎀 Breast · 2026-05-21
  SWOG S1007 RNI analysis
  5-yr LRR <1% with or without RNI in HR+/HER2-, Oncotype ≤25, N1 breast; IDFS not associated with RNI receipt.
• 🫁 Thoracic / Lung · 2026-05-20
  LS-SCLC 54 Gy Hyperfractionated RT
  mOS 60.7 vs 39.5mo (HR 0.55, p=0.003) favoring 54 Gy hyperfractionated RT in LS-SCLC; no added toxicity.
• 🎀 Breast · 2026-05-20
  Proton vs Photon PMRT Capsular Contracture (Zerey et al.)
  MVA HR 1.76 (P=0.083) proton vs photon CC, non-significant; proton+DTI 2yr CC 50% vs photon+DTI 35%.
• 💧 Bladder · 2026-05-19
  Bladder-preserving TMT for MIBC: prognostic factors (ESTRO 2026)
  CLR 63.7% in 369 MIBC pts on TMT; 5-FU-based CRT (OR 4.9) and portal imaging frequency independently predicted CLR.
• 🌰 Prostate · 2026-05-19
  ePLND vs PSMA PET staging in prostate cancer (AUA 2026)
  47.7% of LN mets outside ePLND template; PSMA PET NPV ~96%; RCTs no consistent BCR benefit from routine dissection.
• 🫁 Thoracic / Lung · 2026-05-19
  Single-fraction SABR for primary NSCLC and pulmonary oligometastases (pooled analysis, n=1687)
  2yr LC 90-93%, G3+ AEs 2.9% across 1687 pts treated with SF-SABR at 3 institutions.
• 🌰 Prostate · 2026-05-18
  PEACE 2
  Pelvic RT did not improve cPFS vs prostate-only RT in VHR localized prostate cancer (HR 0.81, p=0.088).
• 🌰 Prostate · 2026-05-18
  HEAT Trial
  SBRT 5 fx non-inferior to EHRT for BF (7% vs 7.4%, p-noninferiority=0.007 at 4.25y) in low-int risk PCa; interim data.
• 👄 Head & Neck · 2026-05-18
  TORPEdO (CRUK/18/010)
  IMPT showed no HR-QoL benefit vs IMRT at 12 months in OPSCC; UW-QoL scores similar across arms to 24 months.
• 👄 Head & Neck · 2026-05-18
  INRT-AIR & DARTBOARD (ENI omission, HNSCC)
  5-yr solitary ENI recurrence 0% in 117 HNSCC pts on AI-assisted INRT omitting elective nodal fields.
• 🌀 GI Lower · 2026-05-18
  OPERA Trial (5-year, rectal preservation)
  76% good response at W14 by clinical exam; 5yr OP 81% cCR vs 77% nCR; W14 assessment safely identifies W&W candidates.
• 🟡 Hepatobiliary · 2026-05-18
  HCC EBRT Multinational IPD Cohort
  BCLC-A mOS 4.6yr, BCLC-0 6.8yr in 4,913-pt IPD cohort; OS comparable to resection and ablation.
• 🎯 Oligometastatic / Mets · 2026-05-18
  EXTEND Trial
  PFS HR 0.54 (95% CI 0.41-0.72, p<0.001) favoring MDT+SOC across histologies in phase II oligometastatic basket RCT; basket-specific signals identified.
• 🫘 Kidney · 2026-05-18
  FASTRACK II (TROG 15.03)
  100% LC at 84 months in primary RCC (N=70) treated with SABR; G3 AE 10%, no grade 4 events or cancer deaths.
• 🎀 Breast · 2026-05-18
  NRG/RTOG 1005
  7-yr IBR 2.6% vs 2.2%, HR 1.31 (90% CI 0.84-2.04); concurrent boost noninferior, reducing treatment to 15 fractions.
• 🎀 Breast · 2026-05-17
  APBI-IMRT Florence
  15-yr IBTR 7.7% vs 4.2% (HR 1.57, p=0.17); no locoregional control, BCSS, or OS difference confirms APBI de-escalation.
• 🎀 Breast · 2026-05-17
  OLIGOMA
  mPFS 35.8 vs 20.4 mo, HR 0.48; first RCT positive for MDT in oligometastatic breast cancer.
• 🎀 Breast · 2026-05-17
  DBCG HYPO
  10-yr G2-3 induration HR 0.76 (19.5% vs 24.7%) favoring 40Gy/15fr; OS and locoregional outcomes equivalent at 12.8yr median f/u.
• 🎀 Breast · 2026-05-17
  IMPORT HIGH
  48Gy SIB: 10-yr IBTR 3.7% vs 3.5% sequential boost, non-inferior; further escalation to 53Gy not beneficial (5.5%).
• 🎀 Breast · 2026-05-17
  EORTC IM-MS (22922/10925)
  20-yr OS null (HR 1.00, p=0.967); BCM benefit offset by non-BCM excess; pN0: no benefit.
• 🎀 Breast · 2026-05-17
  DBCG RT Natural
  9.8% 4-yr LR without PBI vs 1.5% with PBI in pT1N0 low-risk elderly breast conservation; stopped early per pre-specified threshold.
• 🎀 Breast · 2026-05-17
  HypoG-01
  LRR 16% of 118 events; failure patterns comparable between 40 Gy/15fx and 50 Gy/25fx; most in-volume per ESTRO guidelines.
• 🎀 Breast · 2026-05-17
  Dutch BCRG Breast Boost (Modern Systemic Era)
  10-yr IBTR 1.2% with or without boost in 0-2 risk-factor BCT pts; boost omission appears safe in modern systemic era.
• 🎀 Breast · 2026-05-17
  RAPCHEM
  10yr locoregional recurrence <3% with nodal-response-guided RT de-escalation after neoadjuvant in breast cancer.
• 🎯 Oligometastatic / Mets · 2026-05-17
  OligoCare
  88.6% local control at 3yrs across 2447 pts; CRC shows worst local control despite highest delivered dose.
• 🎯 Oligometastatic / Mets · 2026-05-17
  EXTEND
  Phase II RCT of MDT added to SOC for oligometastatic solid tumors, all histology baskets; no effect size in source tweet.
• 🌰 Prostate · 2026-05-17
  PRIME
  SBRT 5fx with pelvic RT: G3+ toxicity <1%, comparable early BFFS to moderate hypo (N~434); mature 4-5yr endpoint pending.
• 🌰 Prostate · 2026-05-17
  PIVOTALboost
  Late G2+ bowel 6.5-8.7%, bladder 16.5-24.1% at 2yr, no increase with focal boost or pelvic node RT vs prostate-only (N=1465).
• 🌰 Prostate · 2026-05-17
  PACE-NODES
  PPN-SBRT increases G≥2 GI toxicity (28% vs 21%) vs prostate-only SBRT; symptoms resolved by 12wk; GU toxicity equivalent; efficacy endpoint pending.
• 🌰 Prostate · 2026-05-17
  RADIOSA
  Post-hoc: SBRT + 6mo ADT vs SBRT alone in oligorecurrent prostate; median MFS 16.6mo vs NR, HR 0.39, p=0.0012.
• 🌰 Prostate · 2026-05-17
  PEACE-2
  Pelvic RT adds no significant cPFS benefit over prostate-only RT in very high-risk PCa with 3yr ADT (HR 0.81, p=0.088) at interim analysis.
• 🫘 Kidney · 2026-05-17
  RCC SBRT 5-year LC
  100% 5-yr local control for RCC treated with SBRT; no additional endpoints in source.
• 👄 Head & Neck · 2026-05-17
  DIREKHT
  Post-op RT de-intensification in HNSCC: contralateral neck sparing and/or primary CTV dose reduction to 56 Gy; no effect size reported in source tweet.